Evaluation of empirical treatment of tuberculosis (TB) before and after the implementation of highly active antiretroviral therapy (HAART) in a teaching hospital (HUCFF/UFRJ), reference for acquired immunodeficiency syndrome (AIDS), in Rio de Janeiro,

F. C. Q. Mello, A. P. M. Lacerda, C. Gounder, F. B. Madeira, A. L. Kritski (Rio de Janeiro, Brazil; Baltimore, United States Of America)

Source: Annual Congress 2001 - What can treatment of TB achieve?

Session: What can treatment of TB achieve?
Session type: Poster Discussion
Number: 2251

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. C. Q. Mello, A. P. M. Lacerda, C. Gounder, F. B. Madeira, A. L. Kritski (Rio de Janeiro, Brazil; Baltimore, United States Of America). Evaluation of empirical treatment of tuberculosis (TB) before and after the implementation of highly active antiretroviral therapy (HAART) in a teaching hospital (HUCFF/UFRJ), reference for acquired immunodeficiency syndrome (AIDS), in Rio de Janeiro,. Eur Respir J 2001; 16: Suppl. 31, 2251

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Impact of highly active antiretroviral therapy (HAART) on the clinical course of Tuberculosis (TB) in Human Immunodeficiency Virus (HIV) infected patients in a universitary hospital in Rio de Janeiro, Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 158s Year: 2003
Cost effectiveness (CE) analysis of polymerase chain reaction (PCR) for diagnosing smear negative pulmonary tuberculosis (SNPT) among inpatients in a teaching hospital, reference for AIDS and tuberculosis (TB), in Rio de Janeiro, Brazil Source: Eur Respir J 2002; 20: Suppl. 38, 582s Year: 2002
Diagnosis of pulmonary tuberculosis using score system in children (HIV positive and negative). Rio de Janeiro, Brazil Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Outcomes of multidrug resistant tuberculosis (MDRTB) control in a 3-year period in a reference centre in Rio de Janeiro, Brazil Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Early negative sputum culture among patients treated for multidrug resistant tuberculosis (MDR-TB) in a government hospital in Rio de Janeiro Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004
Evaluation of a nucleic acid amplification (NAA) test for the diagnosis of smear negative pulmonary tuberculosis (SNPT) at a teaching hospital, in Rio de Janeiro, Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 161s Year: 2003
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
An audit of diagnosis and chemoprophylaxis treatment of latent tuberculosis Infection (LTBI) in TB contact patients in a district general hospital (DGH) in the United Kingdom (UK) Source: Annual Congress 2010 - What is new in the diagnosis of tuberculosis? Year: 2010
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
On-going TB treatment category for TB cases in Iasi county (Romania) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Risk factors for defaulting from antituberculosis treatment (RFDAT) in a community health center in Nova Iguacu - Rio de Janeiro - Brazil Source: Eur Respir J 2002; 20: Suppl. 38, 549s Year: 2002
Trend of acquired drug resistance to main anti TB drugs in the first 7 years of applying DOT strategy in Iasi County, Romania Source: Annual Congress 2007 - Tuberculosis control Year: 2007
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016